Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 3,500 shares of Agios Pharmaceuticals stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $56.14, for a total transaction of $196,490.00. Following the sale, the director now directly owns 86,697 shares in the company, valued at approximately $4,867,169.58. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Thursday, July 20th, Lewis Clayton Jr. Cantley sold 9,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $56.36, for a total transaction of $507,240.00.
  • On Wednesday, June 14th, Lewis Clayton Jr. Cantley sold 2,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $50.87, for a total transaction of $101,740.00.
  • On Thursday, May 25th, Lewis Clayton Jr. Cantley sold 2,036 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $47.10, for a total transaction of $95,895.60.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ AGIO) traded down 0.10% on Friday, reaching $57.17. 345,338 shares of the company were exchanged. The company’s market capitalization is $2.76 billion. Agios Pharmaceuticals, Inc. has a 52 week low of $35.84 and a 52 week high of $67.74. The company’s 50-day moving average is $53.35 and its 200-day moving average is $50.13.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.80) by $0.24. Agios Pharmaceuticals had a negative net margin of 491.54% and a negative return on equity of 71.20%. The company had revenue of $10.51 million for the quarter, compared to analysts’ expectations of $9.65 million. During the same period in the prior year, the business earned ($0.64) EPS. The firm’s quarterly revenue was down 66.4% on a year-over-year basis. On average, equities analysts expect that Agios Pharmaceuticals, Inc. will post ($6.44) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/07/21/agios-pharmaceuticals-inc-agio-director-sells-196490-00-in-stock.html.

A number of hedge funds and other institutional investors have recently modified their holdings of AGIO. BlackRock Inc. boosted its position in shares of Agios Pharmaceuticals by 8,463.5% in the first quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock valued at $126,556,000 after buying an additional 2,141,768 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Agios Pharmaceuticals by 748.0% in the first quarter. Goldman Sachs Group Inc. now owns 649,124 shares of the biopharmaceutical company’s stock valued at $37,909,000 after buying an additional 572,579 shares during the last quarter. Norges Bank acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at about $8,246,000. Redmile Group LLC boosted its position in shares of Agios Pharmaceuticals by 22.2% in the first quarter. Redmile Group LLC now owns 902,578 shares of the biopharmaceutical company’s stock valued at $52,711,000 after buying an additional 164,127 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Agios Pharmaceuticals by 5.2% in the first quarter. Vanguard Group Inc. now owns 2,597,391 shares of the biopharmaceutical company’s stock valued at $151,688,000 after buying an additional 129,159 shares during the last quarter. Institutional investors own 83.83% of the company’s stock.

A number of brokerages have recently weighed in on AGIO. Janney Montgomery Scott lowered shares of Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, June 26th. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 13th. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Credit Suisse Group reaffirmed an “outperform” rating and set a $61.00 target price on shares of Agios Pharmaceuticals in a research note on Tuesday, April 18th. Finally, Zacks Investment Research lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 18th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $62.88.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.